Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

June 4, 2022 updated by: Peking Union Medical College Hospital

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Via Analysis of Immunoinflammation-related Protein Complexes in Blood

The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

100 cases in normal ovarian control group, 100 cases in benign ovarian disease group and 100 cases in malignant ovarian epithelial carcinoma group will be studied. Change regularity of ovarian cancer specific immune inflammation-related protein complexes in blood will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China
        • Recruiting
        • Peking Union Medical College Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

The study population included normal ovarian controls, patients with benign ovarian disease, and patients with malignant epithelial ovarian cancer.

Description

Inclusion Criteria:

  • Female
  • Normal ovary control
  • Ovarian benign disease
  • Ovarian malignant epithelial carcinoma

Exclusion Criteria:

  • Male
  • Age above 70
  • Suffering from other malignant tumors
  • Non-compliant patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immune Inflammation-Related Protein Pomplexes
Time Frame: 2 years
The change of immune inflammation-related protein complexes
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 3, 2022

Primary Completion (ANTICIPATED)

February 3, 2024

Study Completion (ANTICIPATED)

February 3, 2026

Study Registration Dates

First Submitted

June 4, 2022

First Submitted That Met QC Criteria

June 4, 2022

First Posted (ACTUAL)

June 8, 2022

Study Record Updates

Last Update Posted (ACTUAL)

June 8, 2022

Last Update Submitted That Met QC Criteria

June 4, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PUMCH-OC1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe